Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas.

Griffith OL, Chan SR, Griffith M, Krysiak K, Skidmore ZL, Hundal J, Allen JA, Arthur CD, Runci D, Bugatti M, Miceli AP, Schmidt H, Trani L, Kanchi KL, Miller CA, Larson DE, Fulton RS, Vermi W, Wilson RK, Schreiber RD, Mardis ER.

Cell Rep. 2016 Sep 27;17(1):249-260. doi: 10.1016/j.celrep.2016.08.076.

2.

STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.

Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, Schreiber RD.

Breast Cancer Res. 2012 Jan 20;14(1):R16.

3.

Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.

Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA.

Breast Cancer Res. 2011 Jan 28;13(1):R11. doi: 10.1186/bcr2819.

4.

Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Chan SR, Rickert CG, Vermi W, Sheehan KC, Arthur C, Allen JA, White JM, Archambault J, Lonardi S, McDevitt TM, Bhattacharya D, Lorenzi MV, Allred DC, Schreiber RD.

Cell Death Differ. 2014 Feb;21(2):234-46. doi: 10.1038/cdd.2013.116. Epub 2013 Sep 13.

5.

The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.

Hou L, Xu B, Mohankumar KM, Goffin V, Perry JK, Lobie PE, Liu DX.

Int J Oncol. 2012 Dec;41(6):2285-95. doi: 10.3892/ijo.2012.1660. Epub 2012 Oct 15.

PMID:
23064471
7.

Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.

Kavarthapu R, Dufau ML.

Oncotarget. 2017 Apr 18;8(16):27353-27363. doi: 10.18632/oncotarget.16040.

8.

The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Fiorillo AA, Medler TR, Feeney YB, Wetz SM, Tommerdahl KL, Clevenger CV.

Am J Pathol. 2013 Jan;182(1):217-33. doi: 10.1016/j.ajpath.2012.09.021. Epub 2012 Nov 14.

9.

Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.

Barcus CE, O'Leary KA, Brockman JL, Rugowski DE, Liu Y, Garcia N, Yu M, Keely PJ, Eliceiri KW, Schuler LA.

Breast Cancer Res. 2017 Jan 19;19(1):9. doi: 10.1186/s13058-017-0801-1.

10.

Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis.

Caffarel MM, Zaragoza R, Pensa S, Li J, Green AR, Watson CJ.

Cell Death Differ. 2012 Mar;19(3):511-22. doi: 10.1038/cdd.2011.122. Epub 2011 Sep 23.

11.

Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.

Sakamoto K, Triplett AA, Schuler LA, Wagner KU.

Oncogene. 2010 Sep 30;29(39):5359-69. doi: 10.1038/onc.2010.274. Epub 2010 Jul 19.

12.

Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.

Tarulli GA, De Silva D, Ho V, Kunasegaran K, Ghosh K, Tan BC, Bulavin DV, Pietersen AM.

Breast Cancer Res. 2013 Jan 31;15(1):R10. doi: 10.1186/bcr3381.

13.

Endocrine control of canine mammary neoplasms: serum reproductive hormone levels and tissue expression of steroid hormone, prolactin and growth hormone receptors.

Spoerri M, Guscetti F, Hartnack S, Boos A, Oei C, Balogh O, Nowaczyk RM, Michel E, Reichler IM, Kowalewski MP.

BMC Vet Res. 2015 Sep 15;11:235. doi: 10.1186/s12917-015-0546-y.

14.

Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity.

Zhao D, Ma G, Zhang X, He Y, Li M, Han X, Fu L, Dong XY, Nagy T, Zhao Q, Fu L, Dong JT.

J Biol Chem. 2016 Jun 10;291(24):12809-20. doi: 10.1074/jbc.M116.719377. Epub 2016 Apr 20.

15.

Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias.

Schneckenleithner C, Bago-Horvath Z, Dolznig H, Neugebauer N, Kollmann K, Kolbe T, Decker T, Kerjaschki D, Wagner KU, Müller M, Stoiber D, Sexl V.

Oncotarget. 2011 Dec;2(12):1043-54.

16.

Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.

Ramamoorthy S, Tufail R, Hokayem JE, Jorda M, Zhao W, Reis Z, Nawaz Z.

Breast Cancer Res Treat. 2012 Feb;132(1):97-108. doi: 10.1007/s10549-011-1567-2. Epub 2011 May 8.

PMID:
21553290
17.
18.

Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis.

Mapes J, Anandan L, Li Q, Neff A, Clevenger CV, Bagchi IC, Bagchi MK.

J Biol Chem. 2018 Feb 23;293(8):2850-2864. doi: 10.1074/jbc.RA117.000162. Epub 2018 Jan 10.

19.

Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas.

Michel E, Feldmann SK, Kowalewski MP, Bley CR, Boos A, Guscetti F, Reichler IM.

BMC Vet Res. 2012 May 30;8:72. doi: 10.1186/1746-6148-8-72.

20.

Hormone Receptor Expression Analyses in Neoplastic and Non-Neoplastic Canine Mammary Tissue by a Bead Based Multiplex Branched DNA Assay: A Gene Expression Study in Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Samples.

Mohr A, Lüder Ripoli F, Hammer SC, Willenbrock S, Hewicker-Trautwein M, Kiełbowicz Z, Murua Escobar H, Nolte I.

PLoS One. 2016 Sep 20;11(9):e0163311. doi: 10.1371/journal.pone.0163311. eCollection 2016.

Supplemental Content

Support Center